Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Sep;64(9):3614–3619. doi: 10.1128/iai.64.9.3614-3619.1996

Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection.

P A Burghaus 1, B T Wellde 1, T Hall 1, R L Richards 1, A F Egan 1, E M Riley 1, W R Ballou 1, A A Holder 1
PMCID: PMC174271  PMID: 8751907

Abstract

Merozoite surface protein 1 (MSP-1) of Plasmodium falciparum is an antimalarial vaccine candidate. The highly conserved 19-kDa C-terminal processing fragment of MSP-1 (MSP-1(19)) is of particular interest since it contains epitopes recognized by monoclonal antibodies which inhibit the invasion of erythrocytes in vitro. The presence of naturally acquired anti-MSP-1(19) antibodies in individuals exposed to malaria has been correlated with reduced morbidity, and immunization with an equivalent recombinant P. yoelii antigen induces substantial protection against this parasite in mice. We have expressed P. falciparum MSP-1(19) in Escherichia coli as a correctly folded protein and immunized Aotus nancymai monkeys by using the protein incorporated into liposomes and adsorbed to alum. After vaccination, the sera from these animals contained anti-MSP-1(19) antibodies, some of which competed for binding to MSP-1(19) with monoclonal antibodies that inhibit parasite invasion of erythrocytes in vitro. However, after challenge with either a homologous or a heterologous strain of parasite, all animals became parasitemic and required treatment. The immunization did not induce protection in this animal model.

Full Text

The Full Text of this article is available as a PDF (253.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berzins K., Perlmann H., Wåhlin B., Ekre H. P., Högh B., Petersen E., Wellde B., Schoenbechler M., Williams J., Chulay J. Passive immunization of Aotus monkeys with human antibodies to the Plasmodium falciparum antigen Pf155/RESA. Infect Immun. 1991 Apr;59(4):1500–1506. doi: 10.1128/iai.59.4.1500-1506.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blackman M. J., Heidrich H. G., Donachie S., McBride J. S., Holder A. A. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med. 1990 Jul 1;172(1):379–382. doi: 10.1084/jem.172.1.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blackman M. J., Ling I. T., Nicholls S. C., Holder A. A. Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol Biochem Parasitol. 1991 Nov;49(1):29–33. doi: 10.1016/0166-6851(91)90127-r. [DOI] [PubMed] [Google Scholar]
  4. Blackman M. J., Scott-Finnigan T. J., Shai S., Holder A. A. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J Exp Med. 1994 Jul 1;180(1):389–393. doi: 10.1084/jem.180.1.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Burghaus P. A., Holder A. A. Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein. Mol Biochem Parasitol. 1994 Mar;64(1):165–169. doi: 10.1016/0166-6851(94)90144-9. [DOI] [PubMed] [Google Scholar]
  6. Chang S. P., Gibson H. L., Lee-Ng C. T., Barr P. J., Hui G. S. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J Immunol. 1992 Jul 15;149(2):548–555. [PubMed] [Google Scholar]
  7. Chappel J. A., Holder A. A. Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1. Mol Biochem Parasitol. 1993 Aug;60(2):303–311. doi: 10.1016/0166-6851(93)90141-j. [DOI] [PubMed] [Google Scholar]
  8. Cohen J. Bumps on the vaccine road. Science. 1994 Sep 2;265(5177):1371–1373. doi: 10.1126/science.8073271. [DOI] [PubMed] [Google Scholar]
  9. Cooper J. A., Cooper L. T., Saul A. J. Mapping of the region predominantly recognized by antibodies to the Plasmodium falciparum merozoite surface antigen MSA 1. Mol Biochem Parasitol. 1992 Apr;51(2):301–312. doi: 10.1016/0166-6851(92)90080-4. [DOI] [PubMed] [Google Scholar]
  10. Cooper J. A. Merozoite surface antigen-I of plasmodium. Parasitol Today. 1993 Feb;9(2):50–54. doi: 10.1016/0169-4758(93)90031-a. [DOI] [PubMed] [Google Scholar]
  11. Daly T. M., Long C. A. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol. 1995 Jul 1;155(1):236–243. [PubMed] [Google Scholar]
  12. Diggs C. L., Ballou W. R., Miller L. H. The major merozoite surface protein as a malaria vaccine target. Parasitol Today. 1993 Aug;9(8):300–302. doi: 10.1016/0169-4758(93)90130-8. [DOI] [PubMed] [Google Scholar]
  13. Egan A. F., Chappel J. A., Burghaus P. A., Morris J. S., McBride J. S., Holder A. A., Kaslow D. C., Riley E. M. Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infect Immun. 1995 Feb;63(2):456–466. doi: 10.1128/iai.63.2.456-466.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Egan A. F., Morris J., Barnish G., Allen S., Greenwood B. M., Kaslow D. C., Holder A. A., Riley E. M. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis. 1996 Mar;173(3):765–769. doi: 10.1093/infdis/173.3.765. [DOI] [PubMed] [Google Scholar]
  15. Fries L. F., Gordon D. M., Richards R. L., Egan J. E., Hollingdale M. R., Gross M., Silverman C., Alving C. R. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):358–362. doi: 10.1073/pnas.89.1.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Holder A. A. Developments with anti-malarial vaccines. Ann N Y Acad Sci. 1993 Dec 21;700:7–21. doi: 10.1111/j.1749-6632.1993.tb26301.x. [DOI] [PubMed] [Google Scholar]
  17. Howard R. J., Pasloske B. L. Target antigens for asexual malaria vaccine development. Parasitol Today. 1993 Oct;9(10):369–372. doi: 10.1016/0169-4758(93)90085-t. [DOI] [PubMed] [Google Scholar]
  18. Hui G. S., Chang S. P. Plasmodium falciparum: induction of biologically active antibodies to gp195 is dependent on the choice of adjuvants. Exp Parasitol. 1992 Aug;75(1):155–157. doi: 10.1016/0014-4894(92)90131-s. [DOI] [PubMed] [Google Scholar]
  19. Hui G. S., Gosnell W. L., Case S. E., Hashiro C., Nikaido C., Hashimoto A., Kaslow D. C. Immunogenicity of the C-terminal 19-kDa fragment of the Plasmodium falciparum merozoite surface protein 1 (MSP1), YMSP1(19) expressed in S. cerevisiae. J Immunol. 1994 Sep 15;153(6):2544–2553. [PubMed] [Google Scholar]
  20. Høgh B., Marbiah N. T., Burghaus P. A., Andersen P. K. Relationship between maternally derived anti-Plasmodium falciparum antibodies and risk of infection and disease in infants living in an area of Liberia, west Africa, in which malaria is highly endemic. Infect Immun. 1995 Oct;63(10):4034–4038. doi: 10.1128/iai.63.10.4034-4038.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kaslow D. C., Hui G., Kumar S. Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae. Mol Biochem Parasitol. 1994 Feb;63(2):283–289. doi: 10.1016/0166-6851(94)90064-7. [DOI] [PubMed] [Google Scholar]
  22. Ling I. T., Ogun S. A., Holder A. A. Immunization against malaria with a recombinant protein. Parasite Immunol. 1994 Feb;16(2):63–67. doi: 10.1111/j.1365-3024.1994.tb00324.x. [DOI] [PubMed] [Google Scholar]
  23. Miller L. H., Roberts T., Shahabuddin M., McCutchan T. F. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol. 1993 May;59(1):1–14. doi: 10.1016/0166-6851(93)90002-f. [DOI] [PubMed] [Google Scholar]
  24. Müller H. M., Früh K., von Brunn A., Esposito F., Lombardi S., Crisanti A., Bujard H. Development of the human immune response against the major surface protein (gp190) of Plasmodium falciparum. Infect Immun. 1989 Dec;57(12):3765–3769. doi: 10.1128/iai.57.12.3765-3769.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. O'Dea K. P., McKean P. G., Jarra W., Brown K. N. A single gene copy merozoite surface antigen and immune evasion? Parasite Immunol. 1996 Apr;18(4):165–172. doi: 10.1046/j.1365-3024.1996.d01-82.x. [DOI] [PubMed] [Google Scholar]
  26. Pirson P. J., Perkins M. E. Characterization with monoclonal antibodies of a surface antigen of Plasmodium falciparum merozoites. J Immunol. 1985 Mar;134(3):1946–1951. [PubMed] [Google Scholar]
  27. Riley E. M., Allen S. J., Wheeler J. G., Blackman M. J., Bennett S., Takacs B., Schönfeld H. J., Holder A. A., Greenwood B. M. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol. 1992 May;14(3):321–337. doi: 10.1111/j.1365-3024.1992.tb00471.x. [DOI] [PubMed] [Google Scholar]
  28. Riley E. M., Morris-Jones S., Blackman M. J., Greenwood B. M., Holder A. A. A longitudinal study of naturally acquired cellular and humoral immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission. Parasite Immunol. 1993 Sep;15(9):513–524. doi: 10.1111/j.1365-3024.1993.tb00639.x. [DOI] [PubMed] [Google Scholar]
  29. Tolle R., Früh K., Doumbo O., Koita O., N'Diaye M., Fischer A., Dietz K., Bujard H. A prospective study of the association between the human humoral immune response to Plasmodium falciparum blood stage antigen gp190 and control of malarial infections. Infect Immun. 1993 Jan;61(1):40–47. doi: 10.1128/iai.61.1.40-47.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Udhayakumar V., Anyona D., Kariuki S., Shi Y. P., Bloland P. B., Branch O. H., Weiss W., Nahlen B. L., Kaslow D. C., Lal A. A. Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. J Immunol. 1995 Jun 1;154(11):6022–6030. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES